Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects

摘要: The ability of allogeneic hematopoietic cell transplantation (HCT) to cure hematologic malignancies is widely recognized. An important therapeutic aspect HCT in eradicating malignant cells the graft-versus-leukemia (GVL) effect. But GVL effect closely associated with graft-versus-host disease (GVHD) major complication HCT. GVHD remains barrier wider application for a variety diseases. occurs two forms, acute and chronic, both are effects. Recent advances understanding genetic polymorphisms, chemo-cytokine networks, several novel cellular subsets including regulatory T cells, direct mediators cytotoxicity have led improved these complex processes. Animal studies show that modulating cascade may be able reduce undesirable inflammatory aspects while preserving benefits GVL. However, most laboratory observations remain studied well-controlled clinical trials. Multiple effectors involved GVL, although donor recognition host antigens an element this process. Cellular immunotherapy such as leukocyte infusion offers strategy separating Both experimental data suggest post-transplantation can performed relatively safely effectively, optimization patient selection, dose, timing administration all serve limit toxicity enhance potential